Laura Joszt, MA

January 22, 2022

A review of 3 common risk assessment tools for pulmonary arterial hypertension (PAH) found they successfully predict survival for up to 5 years after initial diagnosis.

January 19, 2022

The trastuzumab biosimilar Herzuma was shown to have similar clinical efficacy and safety to the reference product in patients with HER2-positive advanced gastric cancer.

January 15, 2022

Compared with the European Union, biosimilar use in the United States lags, and the US government, health systems, and medical associations all have a role to play.

January 12, 2022

A meta-analysis found an association between Kawasaki disease and subsequent asthma and allergic rhinitis.

January 01, 2022

The most-read chronic obstructive pulmonary disease (COPD) articles of the year covered use of inhaled corticosteroids, palliative care for advanced COPD, and off-label prescribing of COPD therapies.

December 29, 2021

In 2021, there were some changes to recommendations and an important FDA approval for patients with heart failure or who are at risk of heart disease.

December 28, 2021

Articles on treating and protecting patients with blood cancers from COVID-19 and the positive results of zanubrutinib to treat leukemia and lymphoma were among the most read of the year.

December 27, 2021

The most-read AJAC papers of 2021 analyze real-world programs to transform health care and provide insight into physician perspectives of health care and insurance.

December 26, 2021

Behavioral cough therapy should be used as early intervention, said Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

December 26, 2021

Despite being the seventh adalimumab biosimilar approved in the United States, there are none on the market yet.